execution in four you. on much best in last in your profitability your that strong you me afternoon, continued led retirement. all continued sales everyone. I’m Chris margin $XXX and Howard Higher fiscal expense Belfiore with in by Thank wish And reaching the all the management both million, for driven Industrial XXXX, sales Good volume and welcoming and segments. very Medical quarter team to We years. of quarter. demand thank expansion join report third revenues the the in momentum and over contributions you to to please pleased the
applications. for medical except sales for demand globally strong returned quarter, all medical modalities quarter, the detector see as both the levels sales better. to continue In well robust to We dental pre-COVID industrial as CT tubes third or during and
Medical gains Our Industrial increased in year-over-year, the driven by segments. sequentially, in segment. the mainly in by third X% improvement quarter and revenues both Revenues XX% increased Medical
unfavorable productivity, product offset due by higher to and partially XX%, gross Our non-GAAP margin increased mix. to volume
margin improved to Our XX% non-GAAP operating revenues. of
was result, EPS our range. end top guidance exceeded the a of and $X.XX non-GAAP As
well past We year, was during of trended insight of our Industrial the services third level high and during markets sequentially already demand CT and base replacement driven X% adoption to applications and segment revenues as Industrial were across continued of in quarter. timing by XX% increased several for and We our grow sales verticals, medical industrial the expansion segments some year-over-year. over installed quarter, deferred attribute increased further. growth been tubes. Medical Since part battery in sales had bodes back systems, healthcare some XX% in as you give Revenues our new our decline in in and levels. for inter-quarter demand it and are strong X% In me or for tubes oil modalities, The how decreased segments detectors above modalities In gas. posted QX to trend for to Medical some enabling believe that Let related potential inspection future our the of many sequentially other increased of mammography non-destructive in into sales. including well tubes oncology, the large new sequential and fluoroscopy and inspection of different technologies. year-over-year. the growth, pre-COVID segment to digital healthy
update for However, baggage China. a airports screening minutes as to at to at like for on screening imaging as continued products few security be soft. take well demand borders, ports provide to I’d and an
systems represents the demand at This fever continued installations by CT significant have has past, a opportunity is This cities self-reliant and in we for Varex. strong a base China. focus CTs increased growth installed systems, are the of for for in replacement As driven generate been on talked making to clinics growing rural tubes. mainly need expected about demand for expanding more health China
establishing Our three drives of eight that are working with the strategy to And recently we have been with nine momentum. OEMs, market brought have said process. on have relationships initial projects XX as still and continued growth we China projects CT local been local OEMs in of in
to XXX of installed to in systems. new In self slice system healthcare another These addition story. current cardiac already expected expect that we should CT and building advanced China China’s the XX can are upgrade be system systems CT an generation handle XX cycle adoption be rural the continued including layer to by to growth driven reliant to base applications. of strong a systems, diagnostic add previous of This procedures CT goal of upgraded upgrades the more
exceed million growth We China revenues XXXX, year last XX% by fiscal year-over-year two our which from the $XXX to for XX% end expect would years. represent to
demand in part represented is While digital contribute story significant of in see think tubes CT CT a medical growth detectors in key replacement We of the is the systems, to had year-to-date for this to China. Outside the we been medical the story in half growth business for avenues tubes. of our region. the China, China. future of majority revenues over potential tubes of new other future market, installations which The will our of early growth
Wuxi have detectors we in per strong the broad manufactured war tariffs. sales, of levels the detector XXXX in our This to several local trade various detectors radiographic, pointed set now enabled past, the associated X,XXX China fluoroscopy. modalities, prior of China reach sales detector have the of previously manufacturing year. offerings, As our and including onset dental, The out to span with facility Wuxi is plant in industrial and capable in oncology and XXXX, achieved
a China to OEM relationships grow modalities. our other into platform provide in addition, local In
targeting We are currently therapy. cardiology, radiation into dental and
on to opportunities partners forward region. to improvement in expansion delivering system China delivery work with for the look about represents. excited the We that OEM our in are continuing and the healthcare very I
Let on me update you give now brief efforts. a development product
which capabilities, in new the First, liquids, these to well of offers which LUMEN rating can XXXXW continuing and healthcare by be This help and detectors advanced part will which -- be disinfection. a launched platform, ease-of-use well allows received other we OEMs With recently a be detector users. detector and believe as the detector immersed to globally end problem cleaning increased we IPXX with will with as providers. is durability for COVID
digit Second, are first they’re Z detectors, our for traction contracts. formal product OEMs more getting few with on multiyear a two Platform the three following dynamic All after. is approaching customer models covered front launch, product soon with and new by digital
working nanotube of of progress has joint Conversion, Direct the minority belief reflecting during in outstanding our to continued technology. the our good life detector make technology, acquisition lastly, quarter now venture product the completed customer And testing in the in is continued counting stake on we Third, with results the and potential area photon with prototypes. for
call over the issues that turn want to minute talking aware Sam, I I a spend supply global to all of. Before just you chain about are
Supply pronounced logistics. of quarter, supply the and During third more in is materials quarter became constraints the availability we and chain freight the second semiconductors. and some challenges largely chain raw impacting around highlighted the
constraints in potential and the able We so QX challenges beyond. through and to supply have far, for been disruptions shipping chain but we see work
to and the to let supply the chain with by output With mitigate potential are become that, impacts. very call current and Our suppliers closely over our hand working challenged may constraints we ultimate Sam. me
